Dyadic (DYAI) Highlights.
"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Adding Citius (CTXR) $0.55 to Watch List.
Best Presentation at Dawson James Conference.
We attended the Dawson James Conference on October 29th, which had over 20 medtech and biotech companies. The two...
Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Analyst Take: "Potential to be Revolutionary. Dyadic’s C1 shows potential in...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
INVESTOR PRESENTATION
LONGER TERM CHART
Client, see published reports for disclosure and disclaimer details.
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided...
Latest article
Pan Global Resources (PGZ) Investor Presentation.
Pan Global Resources (PGZ, PGZFF) a Proven Ground Exploration company, will doing a non-deal roadshow in the Palm Beach Area tonight. We'll attend and...
Nutriband News Archive
We use a scan and read method of research with all of the Companies we follow. We first scan headlines and post press release...
Report: Initiating Coverage on Nutriband (NTRB) $7.00
This could be one of our most interesting ideas ever. Simple story, simple cap table...plenty of upside potential.
We are planning three reports.
LIVE QUOTE
The first...
